The NEW-AF trial demonstrates that rivaroxaban, a direct oral anticoagulant (DOAC), significantly reduces hospital length of stay compared to warfarin in patients experiencing new-onset atrial fibrillation (AF) following cardiac surgery. This randomized controlled trial involved patients who were randomly assigned to receive either rivaroxaban or warfarin for anticoagulation therapy. The results indicate that rivaroxaban not only shortened the duration of hospitalization but also maintained comparable efficacy and safety profiles to warfarin .
These findings are significant as they suggest that rivaroxaban could be a more efficient alternative to warfarin in managing postoperative AF, potentially leading to improved patient outcomes and resource utilization in cardiac surgical settings. ##Reference## Moonsamy P, Zhao Y, Makarem A, et al. Randomized controlled trial of new oral…
